Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 12/20 | 0.74 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879648 | 0.87 | ITGAL (0.78) | ITGALITGB2ICAM1HPGDKMT2A | |
| SCHEMBL13879658 | 0.86 | ITGAL (0.79) | ITGALITGB2ICAM1HPGD | |
| SCHEMBL13879647 | 0.85 | ITGAL (0.75) | ITGALITGB2ICAM1HPGDKDM4E | |
| SCHEMBL4280136 | 0.85 | ITGAL (1.00) | ITGALITGB2ICAM1KDM4E | |
| SCHEMBL4280143 | 0.85 | ITGAL (1.00) | ITGALITGB2ICAM1KDM4E | |
| SCHEMBL13879649 | 0.84 | ITGAL (0.85) | ITGALITGB2ICAM1HPGDNPC1 | |
| SCHEMBL4289313 | 0.83 | ITGAL (0.78) | ITGALITGB2ICAM1HPGDNPC1 | |
| SCHEMBL4289320 | 0.83 | ITGAL (0.78) | ITGALITGB2ICAM1HPGDNPC1 | |
| SCHEMBL4283960 | 0.82 | ITGAL (0.67) | ITGALITGB2ICAM1HPGDNPC1 | |
| SCHEMBL4283957 | 0.82 | ITGAL (0.67) | ITGALITGB2ICAM1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ITGAL 4495/4885ITGB2 4487/4885ICAM1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.